Quest Diagnostics should be bought on pullbacks, says Maxim Maxim says shares of Quest Diagnostics should be bought on pullbacks following this morning's in-line Q3 results and reduced 2013 guidance. The firm says its long-term thesis remains intact and keeps a Buy rating on the stock.
News For DGX From The Last 14 Days
Check below for free stories on DGX the last two weeks.
NanoString announces adoption of Prosigna Assay by labs, cancer centers NanoString Technologies (NSTG) announced nationwide availability of the Prosigna Breast Cancer Prognostic Gene Signature Assay beginning in Q1. Diagnostic laboratories ARUP Laboratories, Laboratory Corporation of America (LH) and Quest Diagnostics (DGX) have chosen to add the Prosigna Assay to their suites of breast cancer diagnostic tests. NanoString Technologies also announced that laboratories at the University of Alabama at Birmingham Comprehensive Cancer Center and University of North Carolina Lineberger Comprehensive Cancer Center will be among the initial wave of facilities to offer the Prosigna Assay in 2014. Financial terms of the transactions were not disclosed.
On The Fly: Analyst Downgrade Summary Today's noteworthy downgrades include: Edwards Lifesciences (EW) downgraded to Market Perform at Wells Fargo... Home Properties (HME) downgraded to Underweight from Equal Weight at Morgan Stanley... Quest Diagnostics (DGX) downgraded to Underperform from Buy at BofA/Merrill... Tenneco (TEN) downgraded to Outperform from Top Pick at RBC Capital... Old Dominion (ODFL) downgraded to Neutral from Buy at Longbow... China Mobile (CHL) downgraded to Underweight from Overweight at Barclays.